Inipharm is a Frazier-founded company focused on discovering and developing therapies for severe liver diseases. The company is advancing a pipeline of small-molecule therapies that target the activity of HSD17B13, which is a genetically validated target in a range of liver diseases (alcoholic, non-alcoholic, viral, and genetic). Inipharm is led by Frazier Entrepreneur-in-Residence Brian Farmer, who is co-founder of the company and serves as its Chief Executive Officer.
Investors 2
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 11.11.2020 | Series A | $35M | - | finsmes.co... |
Mentions in press and media 6
| Date | Title | Description | Source |
| 12.11.2020 | Inipharm Pulls In $35M Series A Financing |
SEATTLE, WA, Inipharm today announced the close of a $35 million Series A financing round.
>&g... | vcnewsdail... |
| 11.11.2020 | Biopharma startup Inipharm raises $35M in Series A funding | - | vcbay.news... |
| 11.11.2020 | Inipharm Raises $35M in Series A Funding | Inipharm, a Seattle and San Diego-based biopharmaceutical company focused on discovering and develop... | finsmes.co... |
| 11.11.2020 | Small biotech Inipharm lands $35M to take new NASH approach... | A year after Cirius Therapeutics’ lead NASH drug flopped in a large Phase IIb trial, the biote... | endpts.com... |
| 11.11.2020 | Inipharm raises $35M to combat liver diseases with a genetic... | Liver diseases, including fatty liver disease, cirrhosis and various rare diseases, have differing c... | fiercebiot... |
| 11.11.2020 | Inipharm raises $35M to combat liver diseases with a genetic... | Liver diseases, including fatty liver disease, cirrhosis and various rare diseases, have differing c... | fiercebiot... |
